Home Your basket
• Multiple intracranial epi...
   Price 14.00 €
• Posterior cranial fossa a...
   Price 8.50 €
• Surgical exploration of t...
   Price 10.50 €
• Sinonasal hemangiopericyt...
   Price 10.50 €
• Videonystagmography and v...
   Price 10.50 €
• Bronchogenic cyst of the ...
   Price 10.50 €
• Abscess tonsillectomy for...
   Price 10.50 €
• Use of instrumental vocal...
   Price 10.50 €
• Cephalic vein access for ...
   Price 10.50 €
• The uses of computer-assi...
   Price 10.50 €
• Facial dissection applied...
   Price 14.00 €
• Extramuscular soft tissue...
   Price 8.50 €
• Peptide receptor radionuc...
   Price 14.00 €
• Adenoid cystic carcinoma ...
   Price 5.50 €
• Management of a huge amel...
   Price 5.50 €
• Sacrifice was an art: The...
   Price 8.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Congenital bilateral choa...
   Price 5.50 €
• Cervicofacial cellulitise...
   Price 10.50 €
• The “Deglutition Handicap...
   Price 10.50 €
• Forcing the voice : the c...
   Price 5.50 €
• Central auditory processi...
   Price 10.50 €
• Art and nose....
   Price 8.50 €
• The tensegrity concept ap...
   Price 10.50 €
• Advantages of combined th...
   Price 10.50 €
• Paediatric endoscopic sin...
   Price 10.50 €
• Middle ear barotraumas du...
   Price 8.50 €
• Post-traumatic carotid ca...
   Price 8.50 €
• "Sonorous man" - an appro...
   Price 8.50 €
• The benefit of phoniatric...
   Price 8.50 €
• Delayed labyrinthine fist...
   Price 10.50 €
• Validity of cervical ausc...
   Price 12.00 €
• Morbidity of neck dissect...
   Price 15.00 €
• The nasal framework in rh...
   Price 10.50 €
• Vocalab: A new software f...
   Price 8.50 €
• Evaluation and treatment ...
   Price 8.50 €
• Local anesthesia for coch...
   Price 8.50 €
• Total ossicular reconstru...
   Price 10.50 €
• A post-styloid mass revea...
   Price 12.50 €
• Somatic tinnitus (review)...
   Price 12.50 €
• Solitary fibrous tumour o...
   Price 8.50 €
• Life after total laryngec...
   Price 8.50 €
• Predictive factors for su...
   Price 15.00 €
• A survey of current wound...
   Price 5.50 €
• Lingual granuloma of preg...
   Price 5.50 €
• Medical rhinoplasty conce...
   Price 14.00 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Progressive cochleo-vesti...
   Price 5.50 €
• Reconstruction of bone de...
   Price 10.50 €
• Attention deficit disorde...
   Price 10.50 €
• A retrospective study of ...
   Price 10.50 €
• CT scan, MR imaging and a...
   Price 10.50 €
• Teeth and sinuses...
   Price 8.50 €
• Lipoma of the larynx: Fib...
   Price 8.00 €
• Comparison of radical (na...
   Price 10.50 €
• Prevalence of and risk fa...
   Price 10.50 €
• Unusual location of pleom...
   Price 12.50 €
• Cowden syndrome: Otolaryn...
   Price 12.00 €
• Reconstruction after hemi...
   Price 14.00 €
• One-stage surgery of midd...
   Price 8.50 €
• The value of the operatin...
   Price 10.50 €
• Vibrant Soundbridge for h...
   Price 10.50 €
• Endoscopic resection of s...
   Price 10.50 €
• Voice prostheses: long-te...
   Price 10.50 €
• Facial aesthetic lipostru...
   Price 10.50 €
• Vertigo and pathology of ...
   Price 10.50 €
• The place of the myocutan...
   Price 10.50 €
• Type III ossiculoplasty w...
   Price 5.50 €
• Treatment of children wit...
   Price 8.50 €
• Study of the platysma col...
   Price 10.50 €
• Association of Bezold’s a...
   Price 8.50 €
• Minimising radiation dose...
   Price 5.50 €
• Auditory screening in neo...
   Price 8.50 €
• Perilymphatic Gusher as a...
   Price 10.50 €
• Autologous cartilaginous ...
   Price 10.50 €

Total Order 738.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE